Form 4: Krystal Biotech CEO Krish Krishnan Reports Stock Transactions

Krystal Biotech's CEO, Krish Krishnan, reports the vesting of performance stock units (PSUs) and restricted stock units (RSUs), along with associated tax withholding and new grants.

Summary

• On February 28, 2024, Krystal Biotech CEO Krish Krishnan reported transactions involving the company's stock.
• These transactions include the vesting of 12,500 performance stock units (PSUs) granted on February 28, 2023, and the surrender of 5,785 shares for tax withholding related to the PSU vesting at a price of $163.08 per share.
• Additionally, 7,500 PSUs held by Krishnan's spouse, Suma M. Krishnan, vested on the same date, with 3,471 shares surrendered for tax withholding at the same price.
• Krishnan also reported the grant of 35,000 restricted stock units (RSUs) on February 29, 2024, which vest in four equal annual installments starting February 28, 2025.
• Furthermore, 52,500 performance stock units (PSUs) were granted on February 29, 2024, subject to performance criteria for the year ending December 31, 2024, and vesting in two equal annual installments if the criteria are met.
• Following these transactions, Krishnan directly owns 1,637,262 shares and indirectly owns 1,575,882 shares through his spouse, 90,000 shares through the Krishnan Spousal Trust, and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs indicates that performance targets were met, which is a positive sign. The grant of new RSUs and PSUs aligns management's interests with shareholders. However, the surrender of shares for tax withholding is a minor negative.

Positives

• The vesting of PSUs indicates that performance criteria set by the company's Compensation Committee were met.
• The grant of RSUs and PSUs to the CEO aligns his interests with the long-term success of the company.

Negatives

• The surrender of shares for tax withholding reduces the CEO's direct ownership of the company's stock.

Risks

• The value of the RSUs and PSUs is contingent on the company's stock price and the achievement of future performance criteria.
• If performance criteria for the newly granted PSUs are not met, a portion or all of the award will be forfeited.

Future Outlook

The document outlines future vesting dates for RSUs and PSUs, contingent on continued service and achievement of performance criteria. The vesting of RSUs will occur in four equal annual installments starting February 28, 2025. The vesting of PSUs granted on February 29, 2024, is contingent on performance criteria for the year ending December 31, 2024, and will occur in two equal annual installments if the criteria are met.

Industry Context

Stock transactions by company executives are a common occurrence and are closely monitored by investors. These transactions can provide insights into management's confidence in the company's future prospects. The vesting of PSUs indicates that the company has met certain performance targets, which is a positive signal.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
• The vesting schedules and performance criteria for RSUs and PSUs are generally in line with industry standards.
• Comparable companies like CRISPR Therapeutics and Beam Therapeutics also utilize stock-based compensation as part of their executive compensation packages.

Stakeholder Impact

• The vesting of PSUs and grant of RSUs and PSUs can have a positive impact on shareholder value if the company continues to perform well.
• Employees may be motivated by the achievement of performance targets that led to the vesting of PSUs.

Key Dates